Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α–induced angiogenesis in rheumatoid arthritis
Laura M. DeBusk
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorYing Chen
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorToshihide Nishishita
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorJin Chen
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorJames W. Thomas
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorCorresponding Author
Pengnain Charles Lin
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.Search for more papers by this authorLaura M. DeBusk
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorYing Chen
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorToshihide Nishishita
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorJin Chen
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorJames W. Thomas
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Search for more papers by this authorCorresponding Author
Pengnain Charles Lin
Vanderbilt–Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.Search for more papers by this authorAbstract
Objective
Rheumatoid arthritis (RA) is an inflammatory disease and an angiogenic disease. However, the molecular mechanisms promoting angiogenesis in RA are not clearly identified. Our objective was to study the role of an endothelium-specific receptor tyrosine kinase, Tie2, in angiogenesis of inflammatory arthritis.
Methods
Expression of Tie2 and its ligand, angiopoietin 1 (Ang1), in human synovium was examined by immunohistochemistry and Western blot. A novel synovium vascular window model was established to study the role of Tie2 in angiogenesis in vivo. Primary cultured endothelial cells and synoviocytes were used to study tumor necrosis factor α (TNFα)–induced Tie2 and Ang1 expression.
Results
Tie2 was implicated in pathologic angiogenesis. We observed that Tie2 and Ang1 were elevated in human RA synovium. Using a novel collagen-induced arthritis synovial window model, we demonstrated that Tie2 signaling regulated arthritis angiogenesis in vivo. We also showed that Tie2 mediated TNFα-induced angiogenesis in a mouse cornea assay. In addition, we observed that TNFα can regulate Tie2 activation in multiple ways that may involve interactions between endothelial cells and synoviocytes. TNFα up-regulates Tie2 in endothelial cells through nuclear factor κB, and it up-regulates Ang1 in synoviocytes. These findings suggest paracrine regulation of angiogenesis between endothelial cells and synoviocytes.
Conclusion
This study demonstrates that Tie2 regulates angiogenesis in inflammatory synovium. Tie2 signaling is an important angiogenic mediator that links the proinflammatory cytokine TNFα to pathologic angiogenesis.
REFERENCES
- 1 Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457–65.
- 2 Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000; 59Suppl 1: i65–71.
- 3 Walsh DA, Pearson CI. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 2001; 3: 147–53.
- 4 Weber AJ, De Bandt M. Angiogenesis: general mechanisms and implications for rheumatoid arthritis. Joint Bone Spine 2000; 67: 366–83.
- 5 Paleolog EM, Fava RA. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol 1998; 20: 73–94.
- 6 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31.
- 7 Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28: 536–42.
- 8 Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999; 103: 3–4.
- 9 Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8: 1897–909.
- 10 Sato TN, Qin Y, Kozak CA, Audus KL. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci U S A 1993; 90: 9355–8.
- 11 Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161–9.
- 12 Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171–80.
- 13 Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001; 116: 713–20.
- 14 Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999; 40: 1912–20.
- 15 Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998; 77: 51–6.
- 16 Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072–8.
- 17 Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 1998; 95: 8829–34.
- 18 Tanaka S, Sugimachi K, Yamashita Yi Y, Ohga T, Shirabe K, Shimada M, et al. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002; 35: 861–7.
- 19 Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, et al. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 3185–91.
- 20 Hangai M, Moon YS, Kitaya N, Chan CK, Wu DY, Peters KG, et al. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum Gene Ther 2001; 12: 1311–21.
- 21 Uchida T, Nakashima M, Hirota Y, Miyazaki Y, Tsukazaki T, Shindo H. Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Ann Rheum Dis 2000; 59: 607–14.
- 22 Scola MP, Imagawa T, Boivin GP, Giannini EH, Glass DN, Hirsch R, et al. Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice. Arthritis Rheum 2001; 44: 794–801.
- 23 Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM, et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58Suppl 1: I56–60.
- 24 McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999; 134: 1325–31; discussion 1331–2.
- 25 Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992; 140: 539–44.
- 26 Lupia E, Montrucchio G, Battaglia E, Modena V, Camussi G. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996; 26: 1690–4.
- 27 Criscione LG, St. Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002; 14: 204–11.
- 28 Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163–96.
- 29 Montrucchio G, Lupia E, Battaglia E, Passerini G, Bussolino F, Emanuelli G, et al. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 1994; 180: 377–82.
- 30 Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998; 273: 22128–35.
- 31 Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258–65.
- 32 Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015–23.
- 33 Willam C, Koehne P, Jurgensen JS, Grafe M, Wagner KD, Bachmann S, et al. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res 2000; 87: 370–7.
- 34 Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002; 29: 230–9.
- 35 Carteron NL. Cytokines in rheumatoid arthritis: trials and tribulations. Mol Med Today 2000; 6: 315–23.
- 36 Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor κB super-repressor in human intestinal epithelial cells. J Immunol 1998; 160: 410–8.
- 37 Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1994; 91: 215–9.
- 38 Chen Y, Rosloniec E, Goral MI, Boothby M, Chen J. Redirection of T cell effector function in vivo and enhanced collagen-induced arthritis mediated by an IL-2R beta/IL-4R alpha chimeric cytokine receptor transgene. J Immunol 2001; 166: 4163–9.
- 39 Thomas JW, Thieu T-H, Byrd VM, Miller GG. Acidic fibroblast growth factor in synovial cells. Arthritis Rheum 2000; 43: 2152–9.
- 40 Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329: 630–2.
- 41 Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 1987; 84: 5277–81.
- 42
Phillips GD,
Stone AM,
Schultz JC,
Jones BD,
Lisowski MJ,
Goodkin ML, et al.
Tumor necrosis factor alpha (rhTNF) fails to stimulate angiogenesis in the rabbit cornea.
Anat Rec
1996;
245:
53–6.
10.1002/(SICI)1097-0185(199605)245:1<53::AID-AR9>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- 43
Stratmann A,
Acker T,
Burger AM,
Amann K,
Risau W,
Plate KH.
Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.
Int J Cancer
2001;
91:
273–82.
10.1002/1097-0215(200002)9999:9999<::AID-IJC1054>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 44 Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, et al. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 2000; 275: 11216–21.
- 45 Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 1996; 98: 490–6.
